Lamivudine-induced red cell aplasia

Journal of Medical Microbiology

Volumn 57, Issue 8, 2008, Pages 1032-1035

  John, Melanie Anne A ^a   Rhemtula, Yasin A ^b   Menezes, Colin N ^a,b   Grobusch, Martin P ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; COTRIMOXAZOLE; EFAVIRENZ; FERRITIN; LAMIVUDINE; STAVUDINE; TENOFOVIR; TRANSFERRIN;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE APLASIA; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MEAN CORPUSCULAR VOLUME; MICROCYTIC ANEMIA; PANCYTOPENIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PURE RED CELL ANEMIA; SEPSIS; THROMBOCYTE COUNT; TRANSFERRIN BLOOD LEVEL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEMATOCRIT; HIV INFECTIONS; HUMANS; LAMIVUDINE; LEUKOCYTE COUNT; PLATELET COUNT; RED-CELL APLASIA, PURE; TREATMENT OUTCOME;

EID: 50249123242     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.47782-0     Document Type: Article

References (19)

1. Claster, S. (2002). Biology of anemia, differential diagnosis, and treatment options in human immunodeficiency virus infection. J Infect Dis 185 (Suppl 2), S105-S109.
2. Costello, C. (1989). Haematology in HIV Disease. In Postgraduate Haematology, 3rd edn, chapter 23, pp. 380-393. Edited by A. F. Hoffbrand & S. M. Lewis. Oxford: Heinemann.
3. Dornsife, R. E. & Averett, D. R. (1996). In vitro potency of inhibition by antiviral drugs of hematopoeitic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob Agents Chemother 40, 514-519.
4. Fangman, J. J. & Scanden, D. T. (2005). Anemia in HIV infected adults: epidemiology, pathogenesis and clinical management. Curr Hematol Rep 4, 95-102.
5. Forna, F., Liechty, C. C., Solberg, P., Asiimwe, F., Were, W., Mermin, J., Behumbiize, P., Tong, T., Brooks, J. T. & Weidle, P. J. (2007). Clinical toxicity of highly active antiretroviral therapy in a home based AIDS care programme in rural Uganda. J Acquir Immune Defic Syndr 44, 456-462.
6. Hassan, F. (2006). Taking stock of the national ARV programme: what exactly have we done? South Afr J HIV Medicine 23, 32-34.
7. Hester, E. K. & Peacock, J. E., Jr (1998). Profound and unanticipated anemia with lamivudine-zidovudine combination therapy in zidovudine-experienced patients with HIV infection. AIDS 12, 439-440.
8. Khawcharoenporn, T., Shikuma, C. M., Williams, A. E. & Chow, D. C. (2007). Lamivudine associated macrocytosis in HIV infected patients. Int J STD AIDS 18, 39-40.
9. Kumarasamy, N., Vallabhaneni, S., Cecelia, A. J., Yepthomi, T., Balakrishnan, P., Saghayam, S., Flanigan, T. P., Carpenter, C. C., Solomon, S. & Mayer, K. H. (2007). Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr 46, 119-121.
10. Majluf-Cruz, A., Luna-Castanos, G., Trevino-Perez, S., Santoscoy, M. & Nieto-Cisneros, L. (2000). Lamivudine-induced pure red cell aplasia. Am J Hematol 65, 189-191.
11. Moh, R., Danel, C., Sorho, S., Sauvageot, D., Anzian, A., Minga, A., Gomis, O. B., Konga, C., Inwoley, A. & other authors (2005). Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther 10, 615-624.
12. Morris, D. J. (1994). Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf 10, 281-291.
13. Nuesch, R., Srasuebkul, P., Ananworanich, J., Ruxrungthan, K., Phanuphak, P. & Duncombe, C. (2006). Monitoring toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. J Antimicrob Chemother 58, 637-644.
14. Sloand, E. (2005). Hematologic complications of HIV infection. AIDS Rev 7, 187-196.
15. Tseng, A., Conly, J., Fetcher, D., Keystone, D., Salit, I. & Walsley, S. (1998). Precipitous declines in hemoglobin levels associated with combination zidovudine and lamivudine therapy. Clin Infect Dis 27, 908-909.
16. Walker, R. E., Parker, R. I., Kovacs, J. A., Masur, H., Lane, H. C., Carleton, S., Kirk, L. E., Gralnick, H. R. & Fauci, A. S. (1988). Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine. Ann Intern Med 108, 372-376.
17. Weitzel, T., Plettenberg, A., Albrecht, D., Lorenzen, T. & Stoehr, A. (1999). Severe anemia as a newly recognized side effect caused by lamivudine. AIDS 13, 2309-2311.
18. Young, N. S. & Brown, K. E. (2004). Parvovirus B19. N Engl J Med 350, 586-597.
19. Zon, L. I., Arkin, C. & Groopman, J. E. (1988). Hematologic manifestations of the human immunodeficiency virus (HIV). Semin Hematol 25, 208-219.